Vlahov D - Search Results

1

Liver enzyme values in injection drug users with chronic hepatitis C.

Mehta SH, Netski D, Sulkowski MS, Strathdee SA, Vlahov D, Thomas DL. Mehta SH, et al. Among authors: vlahov d. Dig Liver Dis. 2005 Sep;37(9):674-80. doi: 10.1016/j.dld.2005.03.009. Dig Liver Dis. 2005. PMID: 15951255

2

Severity and correlates of liver disease in hepatitis C virus-infected injection drug users.

Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, Vlahov D, Strathdee SA, Boitnott J, Nelson KE, Thomas DL. Rai R, et al. Among authors: vlahov d. Hepatology. 2002 May;35(5):1247-55. doi: 10.1053/jhep.2002.33151. Hepatology. 2002. PMID: 11981775

3

Protection against persistence of hepatitis C.

Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Mehta SH, et al. Among authors: vlahov d. Lancet. 2002 Apr 27;359(9316):1478-83. doi: 10.1016/S0140-6736(02)08435-0. Lancet. 2002. PMID: 11988247

4

Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland.

Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Ompad DC, et al. Among authors: vlahov d. Clin Infect Dis. 2002 Oct 1;35(7):783-8. doi: 10.1086/342063. Epub 2002 Sep 3. Clin Infect Dis. 2002. PMID: 12228813

5

High prevalence of occult hepatitis B in Baltimore injection drug users.

Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. Torbenson M, et al. Among authors: vlahov d. Hepatology. 2004 Jan;39(1):51-7. doi: 10.1002/hep.20025. Hepatology. 2004. PMID: 14752822

6

Mortality risk among new onset injection drug users.

Vlahov D, Wang CL, Galai N, Bareta J, Mehta SH, Strathdee SA, Nelson KE. Vlahov D, et al. Addiction. 2004 Aug;99(8):946-54. doi: 10.1111/j.1360-0443.2004.00780.x. Addiction. 2004. PMID: 15265091

7

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, Vlahov D, Chien D, Shyamala V, Ray SC, Thomas DL. Cox AL, et al. Among authors: vlahov d. Clin Infect Dis. 2005 Apr 1;40(7):951-8. doi: 10.1086/428578. Epub 2005 Mar 3. Clin Infect Dis. 2005. PMID: 15824985

8

A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users.

Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. Mehta SH, et al. Among authors: vlahov d. AIDS. 2005 Oct;19 Suppl 3:S179-89. doi: 10.1097/01.aids.0000192088.72055.90. AIDS. 2005. PMID: 16251816 Review.

9

HIV incidence among injection drug users in Baltimore, Maryland (1988-2004).

Mehta SH, Galai N, Astemborski J, Celentano DD, Strathdee SA, Vlahov D, Nelson KE. Mehta SH, et al. Among authors: vlahov d. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):368-72. doi: 10.1097/01.qai.0000243050.27580.1a. J Acquir Immune Defic Syndr. 2006. PMID: 16980912

10

Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial.

Semba RD, Ricketts EP, Mehta S, Netski D, Thomas D, Kirk G, Wu AW, Vlahov D. Semba RD, et al. Among authors: vlahov d. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):298-303. doi: 10.1097/QAI.0b013e318050d698. J Acquir Immune Defic Syndr. 2007. PMID: 17414930 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

699 results

Search Page

Filters